Eclipse Treatment Planning System Research Articles

Analysis of coplanar and non-coplanar intensity-modulated radiotherapy planning for esophageal cancer

Purpose: The analysis of coplanar intensity modulated radiotherapy (IMRT) and non-coplanar IMRT for the esophageal cancer. Methods: in my study 27 esophageal cancer cases, ten of them were cervical and upper thoracic (Group A) and seventeen were mid and lower thoracic (Group B). Gross target volume (GTV), clinical tumor volume (CTV), and organs at risk (OAR) were contoured by the oncologist in the eclipse treatment planning system. For every case, one coplanar plan & two non-coplanar plans have been generated by the similar general objective function. A descriptive dose-volume histogram (DVH) equation between three plans was then taken out in a table form. Results: 1) In Group A cases with PTV volume less than 100cc, the mean dose and dose gradient of non-coplanar plan were much better than those in coplanar plan. 2) In Group B cases, the conformity index (CI) for coplanar and two non-coplanar plans were 0.68 ± 0.15, 0.43 ± 0.14, and 0.69 ± 0.16, respectively. The V5, V10, V20, and the mean dose to the lung were less in the non-coplanar plans compared to ones in coplanar plan.

Monte Carlo-based independent dose verification of radiosurgery HyperArc plans

PurposeTo investigate the feasibility of using the free PRIMO Monte Carlo software for independent dose check of cranial SRS plans designed with the Varian HyperArc (HA) technique. Materials and methodsIn this study, the PRIMO Monte Carlo software v. 0.3.64.1800 was used with the phase-space files (v. 2, Feb. 27, 2013) provided by Varian for 6 MV flattening-filter-free (FFF) photon beams from a Varian TrueBeam linear accelerator (linac), equipped with a Millennium 120 multileaf collimator (MLC). This configuration was validated by comparing the percentage depth doses (PDDs), lateral profiles and relative output factors (OFs) simulated in a water phantom against measurements for field sizes from 1 × 1 to 40 × 40 cm2. The agreement between simulated and experimental relative dose curves was evaluated using a global (G) gamma index analysis. In addition, the accuracy of PRIMO to model the MLC was investigated (dosimetric leaf gap, tongue and groove, leaf transmission and interleaf leakage).Thirty-five HA SRS plans computed in the Eclipse treatment planning system (TPS) were simulated in PRIMO. The Acuros XB algorithm v. 16.10 (dose to medium) was used in Eclipse. Sixty targets with diameters ranging from 6 to 33 mm were included. Agreement between the dose distributions given by Eclipse and PRIMO was evaluated in terms of 3D global gamma passing rates (GPRs) for the 2 %/2 mm criteria. ResultsAverage GPR greater than 95 % with the 2 %(G)/1 mm criteria were obtained over the PDD and profiles of each field size. Differences between PRIMO calculated and measured OFs were within 0.5 % in all fields, except for the 1 × 1 cm2 with a discrepancy of 1.5 %. Regarding the MLC modeling in PRIMO, an agreement within 3 % was achieved between calculated and experimental doses. Excellent agreement between PRIMO and Eclipse was found for the 35 HA plans. The 3D global GPRs (2 %/2 mm) for the targets and external patient contour were 99.6 % ± 1.1 % and 99.8 % ± 0.5 %, respectively. ConclusionsAccording to the results described in this study, the PRIMO Monte Carlo software, in conjunction with the 6X FFF Varian phase-space files, can be used as secondary dose calculation software to check stereotactic radiosurgery plans from Eclipse using the HyperArc technique.

Varian eclipse stereotactic 5mm cone data commissioning.

Conical collimators are effective and readily available accessories for the field shaping of small stereotactic fields, however the measurements required to accurately characterise the smallest radiation fields are difficult, prone to large errors, and there is little published commissioning data to compare measurements against. The aim of this investigation was to commission the cone dose calculation algorithm of a Varian Eclipse treatment planning system for a Varian 5mm cone attached to a Varian TrueBeam linear accelerator beam-matched to the Varian Golden Beam Data (GBD). Tissue maximum ratios (TMRs) and off-axis ratios (OARs) were measured using PTW 60019 microDiamond and PTW 60018 SRS Diode detectors for a flattening filter free 6MV beam. The output factor (OF) was measured with the microDiamond and EBT-XD film. Results were compared to the GBD for this cone and an OF measured by the Australian Clinical Dosimetry Service during an independent audit. Film dosimetry was used to evaluate Eclipse dose calculations in a solid water phantom and end-to-end accuracy with an anthropomorphic head phantom. Output correction factors were derived from IAEA TRS-483. Gamma analysis was used to compare measured TMRs and OARs, and to compare Eclipse dose planes with film dosimetry results. Comparisons between measured and GBD TMRs passed gamma analysis within the specified criteria, while differences between distances to agreement for OARs measured with different detectors was attributed to different volume averaging characteristics. The OFs measured with the microDiamond and film agreed within measurement uncertainty. It was decided to configure Eclipse with the microDiamond measured OF and the SRS Diode measured TMR and OAR data. This was validated with various comparisons carried out to confirm both measurement accuracy and Eclipse configuration.

Portal dosimetry correction method for validation of single isocenter VMAT plans for multiple brain metastases.

Portal dosimetry is one option for verification of volumetric‐modulated arc therapy (VMAT) planning for multiple brain metastases. However, due to the changing response of the portal imager with photon beam energy, the dose transmitted through closed multileaf collimator (MLC) leaves or narrow MLC gaps may be underestimated by the imager.We present a simple method for correcting for these effects that may be implemented within the Eclipse treatment planning system. We recalculated the predicted portal dose with and without this correction for 20 multiple brain met VMAT plans. Before the correction, 3/20 composite plan fields passed our standard quality assurance (QA) criteria (54/80 individual fields); the average gamma passing rate for the composite plans was 76.9 ± 16.6%, and the average gamma value across the composite plans was 0.67 ± 0.23. After correction, 20/20 composite plan fields passed the QA criteria (80/80 individual fields); the average gamma passing rate for composite plans was 99.2 ± 1.4%, the average gamma value across the composite plans was 0.33 ± 0.90. A measure of plan complexity, the average leaf pair opening could be correlated to the gamma analysis results for the uncorrected plans but not for the corrected plans.

Imaging investigation of small motion target for lung stereotactic body radiotherapy (SBRT)

Purpose: Motion management is important in lung tumor SBRT. Small target four-dimensional computed tomography (4DCT) imaging could give significant target motion information. In this study, Quality of 4DCT for small target was investigated to provide information for treatment planning in SBRT of small target, which is in favor of magnifying the target margin characteristics during 4DCT scan. Method and Materials: A Real Time Position Management (RPM) phantom from Varian Medical System and 6 CT-spot pellets from Beekley Medical were employed for this study. Each pellet was equivalent to a 4mm diameter ball. The CT spot pellets were attached to the RPM phantom. Two pellet set planes formed 8cm distance and generated two speeds which were 0.2cm and 0.4mm per second given a period with 5.0 seconds. With a GE LightSpeedTM RT CT scanner, the phantom was executed with helical scan with 1.25mm slice thickness with and without motion. Then a 4D CT scan in axial cine mode was carried on at the same phantom. The image exams were exported the GE Advantage Workstation for process. The exams were reviewed and sorted into 10 phases retrospectively. The 0% phase image set, 50% phase image set, maximum intensity projection (MIP) image set, and average intensity projection (Ave-IP) image set were exported to the Eclipse treatment planning system for analysis. In image sets, multi-dimensional variables such as center coordinate of pellets, distance between pellets, and volume of the pellets were used for analysis. Results: At 350 HU window width and 40HU window level, image sets from helical scan for the static phantom is used as reference, comparing to helical scan from moving phantom, retrospective MIP, average intensity projection, 0% phase and 50% phase, for pellets moving at 0.4 cm per second, the average coordinate deviation are 0.49cm, 0.22cm, 0.19cm, 0.59cm and 0.06cm with standard deviation 0.83cm, 0.29cm, 0.32cm, 0.69cm, and 0.07cm, the percentage distance differences are 10.2%, 3.3%, 7.3%, 0.1%, and 0.1% with standard deviation of 13.2%, 4.4%, 9.6%, 0.1%, and 0.1%. and the percentage volumes changes are 17.4%, 171.5%, 18.4%, 14.2% and 7.8% with standard deviation at 25.4%, 201.8%, 23.7%, 19.85% and 10%. Conclusions: A simple and sensitive 4DCT quality assurance method was developed by combining Varian RPM phantom and CT-spot pellets from Beekley Medical and it shows that the 50% phase image set is better for SBRT planning. Further study will include dosimetric effect on the small target moving in different directions.

Assessment of dose perturbations for metal stent in photon and proton radiotherapy plans for hepatocellular carcinoma

BackgroundThe present study aimed to investigate the dosimetric impact of metal stent for photon and proton treatment plans in hepatocellular carcinoma.MethodsWith computed tomography data of a water-equivalent solid phantom, dose perturbation caused by a metal stent included in the photon and proton treatment of hepatocellular carcinoma was evaluated by comparing Eclipse and RayStation treatment planning system (TPS) to a Monte Carlo (MC) based dose calculator. Photon and proton plans were created with anterior–posterior/posterior-anterior (AP/PA) fields using a 6 MV beam and AP/PA fields of a wobbling beam using 150 MeV and a 10 cm ridge filter. The difference in dose distributions and dosimetric parameters were compared depending on the stent's positions (the bile duct (GB) and intestinal tract (GI)) and angles (0°, 45°, and 90°). Additionally, the dose variation in the target volume including the stent was comparatively evaluated through dose volume histogram (DVH) analysis. And the comparison of clinical cases was carried out in the same way.ResultsPercentage differences in the dosimetric parameters calculated by MC ranged from − 7.0 to 3.9% for the photon plan and − 33.7 to 4.3% for the proton plan, depending on the angle at which the GB and GI stents were placed, compared to those without the stent. The maximum difference was observed at the minimum dose (Dmin), which was observed in both photon and proton plans in the GB and GI stents deployed at a 90° incidence angle. The parameter differences were greater in the proton plan than in photon plan. The target volume showed various dose variations depending on positions and angles of stent for both beams. Compared with no-stent, the doses within the target volume containing the GI and GB stents for the photon beam were overestimated in the high-dose area at 0°, nearly equal within 1% at 45°, and underestimated at 90°. These doses to the proton beam were underestimated at all angles, and the amount of underdose to the target volume increased with an increase in the stent angle. However, the difference was significantly greater with the proton plan than the photon plan.ConclusionsDose perturbations within the target volume due to the presence of the metal stent were not observed in the TPS calculations for photon and proton beams, but MC was used to confirm that there are dose variations within the target volume. The MC results found that delivery of the treatment beam avoiding the stent was the best method to prevent target volume underdose.

Investigation on the impact of the leaf trailing effect using the Halcyon integrated platform system.

The double-stacked design of the Halcyon multileaf collimator (MLC) presents new challenges for treatment planning systems (TPSs). The leaf trailing effect has recently been described as the result of the interplay between the fluence transmitted through the leaf tip ends of each MLC layer. This effect makes the dosimetric leaf gap (DLG) dependent on the distance between the leaves of different layers (trailing distance) and is not adequately modeled by the Eclipse TPS. The purpose of our study was to investigate and report the dose discrepancies produced by these limitations in clinical plans and to explore how these discrepancies can be mitigated and avoided. The integrated platform with the Halcyon v2 system, Eclipse and Aria v15.6, was used. The dose discrepancies were obtained with electronic portal imaging device (EPID) images and the portal dosimetry software and validated using radiochromic film dosimetry. The results for the AIDA commissioning test and for nine selected clinical beams with the sliding window intensity modulated radiotherapy (dIMRT) technique were thoroughly analyzed and presented. First, the digital imaging and communications in medicine radiotherapy (DICOM RT) plans were exported and the fluences were computed using different leaf tip models, and then were compared. Second, the detailed characteristics of the corresponding leaf sequences were investigated. Finally, modified DICOM RT plans were created in which the noncollimating (backup) leaves were retracted 2mm to increase the leaf trailing distance, the modified plans were imported back into the TPS and the measurements were repeated. Dedicated in-house tools were developed in Python to carry out allanalyses. Dose discrepancies greater than 10% and regions of gamma failure were found in both the AIDA test and clinical beams using static-gantry dIMRT. Fluence analysis highlighted that the discrepancies were due to limitations in the MLC model implemented in the TPS. Analysis of leaf sequences indicated that regions of failure were associated with very low leaf speeds and virtually motionless leaves within the beam aperture. Some of these discrepancies were mitigated by increasing the trailing distance of the noncollimating leaves without affecting the beam aperture, but this strategy was not possible in regions where the leaves from both layers actively defined the beamaperture. Current limitations of the MLC model in Eclipse produced discrepancies between calculated and delivered doses in clinical beams that caused plan-specific quality assurance failures and interruptions in the clinical workflow. Careful evaluation of the clinical plans produced by Eclipse for the Halcyon is recommended, especially for static gantry dIMRT treatments. Some characteristics of leaf sequences are problematic and should be avoided in clinical plans and, in general, a better leaf tip model is needed. This is particularly important in adaptive radiotherapy treatments, where the accuracy and reliability of TPS dose calculations are of the utmostimportance.

Evaluation of the dosimetric and radiobiological parameters in four radiotherapy regimens for synchronous bilateral breast cancer.

This study is to investigate the optimal treatment option for synchronous bilateral breast cancer (SBBC) by comparing dosimetric and radiobiological parameters of intensity‐modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) plans using single and dual isocenters.Twenty patients with SBBC without lymph node involvement were selected retrospectively. Four treatment plans were generated for each patient using the Eclipse treatment planning system (Varian Medical System, Palo Alto, CA, USA) following two delivery techniques with two isocenter conditions—IMRT using a single isocenter (IMRT_Iso1), VMAT using a single isocenter (VMAT_Iso1), IMRT using dual isocenters (IMRT_Iso2), and VMAT using dual isocenters (VMAT_Iso2). A dose of 42.56 Gy in 16 fractions was prescribed for the planning target volume (PTV). All plans were calculated using the Acuros XB algorithm and a photon optimizer for a 6‐MV beam of a Vital Beam linear accelerator. PTV‐related dosimetric parameters were analyzed. Further, the homogeneity index, conformity index, and conformation number were computed to evaluate plan quality. Dosimetric parameters were also measured for the organs at risk (OARs). In addition, the equivalent uniform dose corresponding to an equivalent dose related to a reference of 2 Gy per fraction, the tumor control probability, and the normal tissue complication probability were calculated based on the dose–volume histogram to investigate the radiobiological impact on PTV and OARs.IMRT_Iso1 exhibited similar target coverage and a certain degree of dosimetric improvement in OAR sparing compared to the other techniques. It also exhibited some radiobiological improvement, albeit insignificant. Although IMRT_Iso1 significantly increased monitor unit compared to VMAT_Iso1, which is the best option in terms of delivery efficiency, there was only a 22% increase in delivery time. Therefore, in conclusion, IMRT_Iso1, the complete treatment of which can be completed using a single setup, is the most effective method for treating SBBC.

Clinical Evaluation of Fiducial Marker Pre-Planning for Virtual Bronchoscopic Navigation Implantation in Lung Tumour Patients Treated With CyberKnife.

PurposeFor the treatment of invisible lung tumours with CyberKnife (CK), fiducial markers (FMs) were implanted as an internal surrogate under virtual bronchoscopic navigation (VBN). This research aims to study the benefits of introducing an additional procedure in assigning the optimal FM positions using a pre-procedure planning system and performing virtual simulation before implantation. The objectives were 1) to reduce the duration of the FM implantation procedure, 2) to reduce the radiation exposure in dose area product (DAP) (dGy*cm2) to patients, and 3) to increase the number of FMs implanted around the tumour.Methods and MaterialsThis study is retrospective, single-centre, and observational in nature. A total of 32 patients were divided into two groups. In Group 1, 18 patients underwent conventional VBN FM implantation. In Group 2, 14 patients underwent additional pre-procedure planning and simulation. The steps of pre-procedure planning include 1) importing CT images into the treatment planning system (Eclipse, Varian Medical Systems, Inc.) and delineating five to six FMs in their ideal virtual positions and 2) copying the FM configuration into VBN planning software (LungPoint Bronchus Medical, Inc.) for verification and simulation. Finally, the verified FMs were deployed through VBN with the guidance of the LungPoint planning software.ResultsA total of 162 FMs were implanted among 35 lesions in 32 patients aged from 37 to 92 (median = 66; 16 men and 16 women). Results showed that 1) the average FM insertion time was shortened from 41 min (SD = 2.05) to 23 min (SD = 1.25), p = 0.00; 2) the average absorbed dose of patients in DAP was decreased from 67.4 cGy*cm2 (SD = 14.48) to 25.3 cGy*cm2 (SD = 3.82), p = 0.01 (1-tailed); and 3) the average number of FMs implanted around the tumour was increased from 4.7 (SD = 0.84) to 5.6 (SD = 0.76), p = 0.00 (1-tailed).ConclusionPre-procedure planning reduces the FM implantation duration from 41.1 to 22.9 min, reduces the radiation exposure in DAP from 67.4 to 25.3 dGy*cm2, and increases the number of FMs inserted around the tumour from 4.7 to 5.6.

The development of a deep reinforcement learning network for dose-volume-constrained treatment planning in prostate cancer intensity modulated radiotherapy

Although commercial treatment planning systems (TPSs) can automatically solve the optimization problem for treatment planning, human planners need to define and adjust the planning objectives/constraints to obtain clinically acceptable plans. Such a process is labor-intensive and time-consuming. In this work, we show an end-to-end study to train a deep reinforcement learning (DRL) based virtual treatment planner (VTP) that can behave like a human to operate a dose-volume constrained treatment plan optimization engine following the parameters used in Eclipse TPS for high-quality treatment planning. We considered the prostate cancer IMRT treatment plan as the testbed. The VTP took the dose-volume histogram (DVH) of a plan as input and predicted the optimal strategy for constraint adjustment to improve the plan quality. The training of VTP followed the state-of-the-art Q-learning framework. Experience replay was implemented with epsilon-greedy search to explore the impacts of taking different actions on a large number of automatically generated plans, from which an optimal policy can be learned. Since a major computational cost in training was to solve the plan optimization problem repeatedly, we implemented a graphical processing unit (GPU)-based technique to improve the efficiency by 2-fold. Upon the completion of training, the established VTP was deployed to plan for an independent set of 50 testing patient cases. Connecting the established VTP with the Eclipse workstation via the application programming interface, we tested the performance the VTP in operating Eclipse TPS for automatic treatment planning with another two independent patient cases. Like a human planner, VTP kept adjusting the planning objectives/constraints to improve plan quality until the plan was acceptable or the maximum number of adjustment steps was reached under both scenarios. The generated plans were evaluated using the ProKnow scoring system. The mean plan score (± standard deviation) of the 50 testing cases were improved from 6.18 ± 1.75 to 8.14 ± 1.27 by the VTP, with 9 being the maximal score. As for the two cases under Eclipse dose optimization, the plan scores were improved from 8 to 8.4 and 8.7 respectively by the VTP. These results indicated that the proposed DRL-based VTP was able to operate the in-house dose-volume constrained TPS and Eclipse TPS to automatically generate high-quality treatment plans for prostate cancer IMRT.

Normal tissue objective (NTO) tool in Eclipse treatment planning system for dose distribution optimization

Abstract Introduction: The purpose of this study was to determine the best normal tissue objective (NTO) values based on the dose distribution from brain tumor radiation therapy. Material and methods: The NTO is a constraint provided by Eclipse to limit the dose to normal tissues by steepening the dose gradient. The multitude of NTO setting combinations necessitates optimal NTO settings. The Eclipse supports manual and automatic NTOs. Fifteen patients were re-planned using NTO priorities of 1, 50, 100, 150, 200, and 500 in combination with dose fall-offs of 0.05, 0.1, 0.2, 0.3, 0.5, 1 and 5 mm-1. NTO distance to planning target volume (PTV), start dose, and end dose were 1 mm, 105%, and 60%, respectively, for all plans. In addition, planning without the NTO was arranged to find out its effect on planning. The prescription dose covered 95% of the PTV. Planning was evaluated using several indices: conformity index (CI), homogeneity index (HI), gradient index (GI), modified gradient index (mGI), comprehensive quality index (CQI), and monitor unit (MU). Differences among automatic NTO, manual NTO, and without NTO were evaluated using the Wilcoxon signed-rank test. Results: Comparisons obtained without and with manual NTO were: CI of 0.77 vs. 0.96 (p = 0.002), GI of 4.52 vs. 4.69 (p = 0.233), mGI of 4.93 vs. 3.95 (p = 0.001), HI of 1.10 vs. 1.10 (p = 0.330), and MU/cGy of 3.44 vs. 3.42 (p = 0.460). Planning without NTO produced a poor conformity index. Comparisons of automatic and manual NTOs were: CI of 0.92 vs. 0.96 (p = 0.035), GI of 5.25 vs. 4.69 (p = 0.253), mGI of 4.46 vs. 3.95 (p = 0.001), HI of 1.09 vs. 1.10 (p = 0.004), MU/cGy of 3.31 vs. 3.42 (p = 0.041). Conclusions: Based on these results, manual NTO with a priority of 100 and dose fall-off 0.5 mm-1 was optimal, as indicated by the high dose reduction in normal tissue.

Evaluation of SRS MapCHECK with StereoPHAN phantom as a new pre-treatment system verification for SBRT plans

Abstract Introduction: The aim of this study was to evaluate the new 2-Dimensional diode array SRS MapCHECK (SunNuclear, Melbourne, USA) with dedicated phantom StereoPHAN (SunNuclear, Melbourne, USA) for the pre-treatment verification of the stereotactic body radiotherapy (SBRT). Material and methods: For the system, the short and mid-long stability, dose linearity with MU, angular dependence, and field size dependence (ratio of relative output factor) were measured. The results of verification for 15 pre-treatment cancer patients (5 brains, 5 lungs, and 5 livers) performed with SRS MapCHECK and EBT3 Gafchromic films were compared. All the SBRT plans were optimized with the Eclipse (v. 15.6, Varian, Palo Alto, USA) treatment planning system (TPS) using the Acuros XB (Varian, Palo Alto, USA) dose calculation algorithm and were delivered to the Varian EDGE® (Varian, Palo Alto, USA) accelerator equipped with a high-definition multileaf collimator. The 6MV flattening-filter-free beam (FFF) was used. Results: Short and mid-long stability of SRS MapCHECK was very good (0.1%-0.2%), dose linearity with MU and dependence of the response of the detector on field size results were also acceptable (for dose linearity R2 = 1 and 6% difference between microDiamond and SRS MapCHECK response for the smallest field of 1 × 1 cm2). The angular dependence was very good except for the angles close to 90° and 270°. For pre-treatment plan verification, the gamma method was used with the criteria of 3% dose difference and 3 mm distance to agreement (3%/3 mm), and 2%/2 mm, 1%/1 mm, 3%/1 mm, and 2%/1 mm. The highest passing rate for all criteria was observed on the SRS MapCHECK system. Conclusions: It is concluded that SRS MapCHECK with StereoPHAN has sufficient potential for pre-treatment verification of the SBRT plans, so that verification of stereotactic plans can be significantly accelerated.

Accuracy of the doses computed by the Eclipse treatment planning system near and inside metal elements

Metal artefacts degrade clinical image quality which decreases the confidence of using computed tomography (CT) for the delineation of key structures for treatment planning and leads to dose errors in affected areas. In this work, we investigated accuracy of doses computed by the Eclipse treatment planning system near and inside metallic elements for two different computation algorithms. An impact of CT metal artefact reduction methods on the resulting calculated doses has also been assessed. A water phantom including Gafchromic film and metal inserts was irradiated (max dose 5 Gy) using a 6 MV photon beam. Three materials were tested: titanium, alloy 600, and tungsten. The phantom CT images were obtained with the pseudo-monoenergetic reconstruction (PMR) and the iterative metal artefact reduction (iMAR). Image sets were used for dose calculation using an Eclipse treatment planning station (TPS). Monte Carlo (MC) simulations were used to predict the true dose distribution in the phantom allowing for comparison with doses measured by film and calculated by TPS. Measured and simulated percentage depth doses (PDDs) were not statistically different (p > 0.618). Regional differences were observed at edges of metallic objects (max 8% difference). However, PDDs simulated with and without film were statistically different (p < 0.002). PDDs calculated by the Acuros XB algorithm based on the dose-to-medium approach best matched the MC reference regardless of the CT reconstruction methods and inserts used (p > 0.078). PDDs obtained using other algorithms significantly differ from the MC values (p < 0.011). The Acuros XB algorithm with a dose-to-medium approach provides reliable dose calculation in all metal regions when using the Varian system. The inability of the AAA algorithm to model backscatter dose significantly limits its clinical application in the presence of metal. No significant impact on the dose calculation was found for a range of metal artefact reduction strategies.

Dosimetric Importance of Implementing Jaw Tracking Technique in Radiotherapy Treatment Plan Execution.

Objective: To study the dosimetric importance of Jaw tracking technique in reducing the doses to organs at risk (OAR) while achieving the optimal dose coverage for the target. Methods:We retrospectively selected ten Glioblastoma cases and for each patient, two plans were created namely Static Jaw Technique Dynamic Intensity Modulated Radiotherapy plan and Jaw Tracking Technique D-IMRT plan with 6 MV for Varian Truebeam™ STx machine using Eclipse Treatment planning system. Both plans were analyzed and compared based on various dosimetric parameters for Planning Target Volume (PTV) and OARs. The dose agreement between the Portal dose image prediction and the portal dosimetry measurement was also analysed using gamma analysis criteria of 3%/3mm, 2%/2mm and 1%/1mm of dose distance/distance-to-agreement. Results: The dosimetric parameters evaluated for both plans showed that most of the parameters gave significant P values, where D50% of PTV showed a mean difference (Δ) of 0.45 with significant P value, 0.0104. Similarly mean dose, D2%, D98%, D80% to PTV, Conformity Index and Conformation number showed Δ values of 0.45, 0.51, 0.41, 0.40, 0.02 and 0.01 with their significant P values as 0.0138, 0.0172, 0.0313, 0.0466, 0.0279, 0.0561 respectively. The Δ values and significant P values obtained among OARs are 0.54;0.0224 for brainstem, 0.54;0.0017 for RT optic nerve, 0.52;0.0001 for LT optic nerve, 0.59;0.0040 for optic chiasm and for the healthy tissues it showed the values with their mean dose, V5 and V30 parameters as 0.19;0.0115, 0.59;0.0067 and 0.25;0.0125 respectively. The JTT plans showed better passing results of gamma analysis criteria when compared to SJT plans. Conclusion: The findings in the studies emphasize the importance of using JTT technique in the radiotherapy treatment plans as it lowers the risk of acute or late toxicity and secondary radiogenic cancers in patients by reducing the OAR doses and achieves better tumor control.

Integration of an Independent Monitor Unit Check for High-Magnetic-Field MR-Guided Radiation Therapy System.

PurposeCommercial independent monitor unit (IMU) check systems for high-magnetic-field MR-guided radiation therapy (RT) systems are lacking. We investigated the feasibility of adopting an existing treatment planning system (TPS) as an IMU check for online adaptive radiotherapy using 1.5-Tesla MR-Linac.MethodsThe 7-MV flattening filter free (FFF) beam and multi-leaf collimator (MLC) models of a 1.5-T Elekta Unity MR-Linac within Monte Carlo-based Monaco TPS were used to generate an optimized beam model in Eclipse TPS. The MLC dosimetric leaf gap of the beam in Eclipse was determined by matching the dose distribution of Eclipse-generated intensity-modulated radiation therapy (IMRT) plans using the Analytical Anisotropic Algorithm (AAA) algorithm to Monaco plans. The plans were automatically adjusted for different source-to-axis distances (SADs) between the two systems. For IMU check, the treatment plans developed in Monaco were transferred to Eclipse to recalculate the dose using AAA. A plug-in within Eclipse was created to perform a 2D gamma analysis of the AAA and Monte Carlo dose distribution on a beam’s eye view parallel plane. Monaco dose distribution was shifted laterally by 2 mm during gamma analysis to account for the impact of magnetic field on electron trajectories. Eclipse doses for posterior beams were corrected for both the Unity couch and the posterior MR coil attenuation. Thirteen patients, each with 4–5 fractions for a variety of tumor sites (pancreas, rectum, and prostate), were tested.ResultsAfter thorough commissioning, the method was implemented as part of the standard clinical workflow. A total of 62 online plans, each with approximately 15 beams, were evaluated. The average per-beam gamma (3%/3 mm) pass rate for plans was 97.9% (range, 95.9% to 98.8%). The average pass rate per beam for all 932 beams used in these plans was 97.9% ± 1.9%, with the lowest per-beam gamma pass rate at 88.4%. The time for the process was within 3.2 ± 0.9 min.ConclusionThe use of a second planning system provides an efficient way to perform IMU checks with clinically acceptable accuracy for online adaptive plans on Unity MR-Linac. This is essential for meeting the safety requirements for second checks as outlined in American Association of Physicists in Medicine Task Group (AAPM TG) reports 114 and 219.

Dosimetric Comparison of Ultra-Hypofractionated and Conventionally Fractionated Radiation Therapy Boosts for Patients with High-Risk Prostate Cancer.

Recent comparison of an ultra-hypofractionated radiotherapy (UF-RT) boost to a conventionally fractionated (CF-RT) option showed similar toxicity and disease control outcomes. An analysis of the treatment plans for these patients is needed for evaluating calculated doses for different organs, treatment beam-on time, and requirements for human and financial resources. Eighty-six plans for UF-RT and 93 plans for CF-RT schemes were evaluated. The biologically equivalent dose, EQD2, summed for the first phase and the boost, was calculated for dose-volume parameters for organs at risk (OARs), as well as for the PTV1. ArcCHECK measurements for the boost plans were used for a comparison of planned and delivered doses. Monitor units and beam-on times were recorded by the Eclipse treatment planning system. Statistical analysis was performed with a significance level of 0.05. Dosimetric parameter values for OARs were well within tolerance for both groups. EQD2 for the PTV1 was on average 84 Gy for UF-RT patients and 76 Gy for CF-RT patients. Gamma passing rate for planned/delivered doses comparison was above 98% for both groups with 3 mm/3% distance to agreement/dose difference criteria. Total monitor units per fraction were 647 ± 94 and 2034 ± 570 for CF-RT and UF-RT, respectively. The total delivery time for boost radiation for the patients in the UF-RT arm was, on average, four times less than the total time for a conventional regimen with statistically equal clinical outcomes for the two arms in this study.

Proceedings to the 7th Annual Conference of the Particle Therapy Cooperative Group North America (PTCOG-NA)

Proceedings to the 7th Annual Conference of the Particle Therapy Cooperative Group North America (PTCOG-NA)

A Dosimetric Parameter Reference Look-Up Table for GRID Collimator-Based Spatially Fractionated Radiation Therapy.

Simple SummaryDose prescription for the inhomogeneous dosing in spatially fractionated radiation therapy (SFRT) is challenging, and further hampered by the inability of several planning systems to incorporate complex SFRT dose patterns. We developed dosing reference tables for an inventory of tumour scenarios and tested their accuracy with water phantom measurements of GRID therapy, delivered by a standard commercial GRID collimator. We find that dose heterogeneity parameters and EUD modeling are consistent across tumour sizes, configurations, and treatment depths. These results suggest that the developed reference tables can be used as a practical clinical resource for clinical decision-making on GRID therapy and to facilitate heterogeneity dose estimates in clinical patients when this commercially available GRID device is used.Computations of heterogeneity dose parameters in GRID therapy remain challenging in many treatment planning systems (TPS). To address this difficulty, we developed reference dose tables for a standard GRID collimator and validate their accuracy. The .decimal Inc. GRID collimator was implemented within the Eclipse TPS. The accuracy of the dose calculation was confirmed in the commissioning process. Representative sets of simulated ellipsoidal tumours ranging from 6–20 cm in diameter at a 3-cm depth; 16-cm ellipsoidal tumours at 3, 6, and 10 cm in depth were studied. All were treated with 6MV photons to a 20 Gy prescription dose at the tumour center. From these, the GRID therapy dosimetric parameters (previously recommended by the Radiosurgery Society white paper) were derived. Differences in D5 through D95 and EUD between different tumour sizes at the same depth were within 5% of the prescription dose. PVDR from profile measurements at the tumour center differed from D10/D90, but D10/D90 variations for the same tumour depths were within 11%. Three approximation equations were developed for calculating EUDs of different prescription doses for three radiosensitivity levels for 3-cm deep tumours. Dosimetric parameters were consistent and predictable across tumour sizes and depths. Our study results support the use of the developed tables as a reference tool for GRID therapy.

Abstract P3-19-10: Subcutaneous layer dosimetry of the breast and chest wall at clinical beam energies without bolus: A Monte Carlo and analytical anisotropic algorithm (AAA) calculation study

Abstract PURPOSE: Breast skin thickness is 3 mm (1). The subcutaneous layer (SL) lies immediately beneath the skin and is at risk for local recurrence after breast cancer surgery and adjuvant radiotherapy. As the SL lies within the buildup region for megavoltage radiation treatment, placement of bolus for patients receiving chest wall (CW) radiotherapy (RT) is routine at many centers. The dermal toxicity of bolus is well known: in 12 studies of CW RT, the pooled risk of Grade 3 acute toxicity is 9.6% with bolus and 1.2% without bolus (2). Meanwhile, bolus is rarely used after breast-conserving surgery (BCS) RT for patients with similar cancers. This study examines variation in tangential RT dose coverage of the SL in the intact breast and bolus-free CW with clinically relevant photon beam energies using Monte Carlo (MC) calculations and a commercial treatment planning system (TPS). METHODS: Thirty CT datasets from patients without skin involvement were identified. There were two groups of patients: 15 treated with BCS RT and 15 treated with CW RT. In each group, 5-patient subgroups had tangent-beam RT planned without bolus with 6, 10, and 15 MV photons, respectively, using the Analytical Anisotropic Algorithm (AAA) algorithm (v.13.6.23) in Eclipse v.15.6 (Varian Medical Systems Inc., Palo Alto, CA). On each CT, the SL was segmented as a high-resolution shell from 3 to 5 mm below the body contour in the Eclipse TPS v.15.6 (Varian Medical Systems Inc., Palo Alto, CA). A 1x1x1 mm MC dose simulation was performed using EGSnrc code (BEAMnrc/DOSXYZnrc). The MC dose distributions were imported back into the TPS for comparison with AAA calculations. The V95% and V90% for the SL were calculated for each case and the mean V95% and V90% were reported for each subgroup. A t-test was used with a two-sided alpha = 0.05 for statistical analysis. RESULTS: The mean separation increased with use of higher energies for both BCS and CW RT. The MC-calculated mean SL V90% and V95% were higher for CW RT than for BCS RT at each energy. The V90% coverage was 91.5% for CW and 74.4 % for BCS at 6 MV (p&amp;lt;0.001), 89.3% for CW and 61.3% for BCS (p&amp;lt;0.001) at 10 MV and 87.1% for CW and 60.9% for BCS (p&amp;lt;0.001) at 15 MV (Table 1). For SL V95% the CW coverage was higher than the BCS coverage for every energy. For SL V90% at 6 MV, the AAA and MC calculations agreed within 2.5%, with the MC being slightly higher. The agreement between AAA and MC decreased for higher energies with MC reporting higher SL V90% coverage by up to 16.3%. The higher MC-calculated dose to the SL is consistent with the literature (3). CONCLUSION: MC and AAA SL dose calculations agreed well for 6 MV, but AAA underestimated the dose for 10 and 15 MV. For 6-15 MV photons, the MC-calculated dosimetric coverage of the SL is higher for CW RT than BCS RT. Since radiation oncologists are satisfied with the SL coverage by BCS RT, bolus is not needed for CW RT, because, without bolus, CW RT delivers a higher SL dose than BCS RT. REFERENCES:. 1.Pope TL Jr, et al.J Can Assoc Radiol. 1984 Dec;35(4):365-8. PMID: 6526847. 2.Dahn HM, et al. Crit Rev Oncol Hematol. 2021 Jun 5;163:10339. PMID: 34102286. 3.Panettieri V, et al., Radiother Oncol 2009; 93: 94-101 Table 1.Monte Carlo calculated mean V90% and V95% for Breast and Chest Wall for each energyV95%V95%V95%V90%V90%V90%Energy(MV)Chest Wall(Mean)Breast. (Mean)p-valueChest Wall(Mean)Breast. (Mean)p-value661.9%35.1%&amp;lt;0.00191.5%74.4%&amp;lt;0.0011065.2%39.7%&amp;lt;0.00189.3%61.3%&amp;lt;0.0011561.7%38.9%0.01287.1%60.9%&amp;lt;0.001 Citation Format: Dylan Narinesingh, Alan Nichol, Alanah Bergman, Tony Popescu. Subcutaneous layer dosimetry of the breast and chest wall at clinical beam energies without bolus: A Monte Carlo and analytical anisotropic algorithm (AAA) calculation study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-19-10.

Assessment of efficacy in automated plan generation for Varian Ethos intelligent optimization engine.

Varian Ethos, a new treatment platform, is capable of automatically generating treatment plans for initial planning and for online, adaptive planning, using an intelligent optimization engine (IOE). The primary purpose of this study is to assess the efficacy of Varian Ethos IOE for auto‐planning and intercompare different treatment modalities within the Ethos treatment planning system (TPS). A total of 36 retrospective prostate and proximal seminal vesicles cases were selected for this study. The prescription dose was 50.4 Gy in 28 fractions to the proximal seminal vesicles, with a simultaneous integrated boost of 70 Gy to the prostate gland. Based on RT intent, three treatment plans were auto‐generated in the Ethos TPS and were exported to the Eclipse TPS for intercomparison with the Eclipse treatment plan. When normalized for the same planning target volume (PTV) coverage, Ethos plans D max% were 108.1 ± 1.2%, 108.4 ± 1.6%, and 109.6 ± 2.0%, for the 9‐field IMRT, 12‐field IMRT, and 2‐full arc VMAT plans, respectively. This compared well with Eclipse plan D max% values, which was 108.8 ± 1.4%. OAR indices were also evaluated for Ethos plans using Radiation Therapy Oncology Group report 0415 as a guide and were found to be comparable to each other and the Eclipse plans. While all Ethos plans were comparable, we found that, in general, the Ethos 12‐field IMRT plans met most of the dosimetric goals for treatment. Also, Ethos IOE consistently generated dosimetrically hotter VMAT plans versus IMRT plans. On average, Ethos TPS took 13 min to generate 2‐full arc VMAT plans, compared to 5 min for 12‐field IMRT plans. Varian Ethos TPS can generate multiple treatment plans in an efficient time frame and the quality of the plans could be deemed clinically acceptable when compared to manually generated treatment plans.